| Literature DB >> 35334728 |
Zhong Wang1, Xiuying Yang2, Nicholas Zhou Lee3, Xudong Cao1,4.
Abstract
Aptamers are short and single-stranded DNA or RNA molecules with highly programmable structures that give them the ability to interact specifically with a large variety of targets, including proteins, cells, and small molecules. Multivalent aptamers refer to molecular constructs that combine two or more identical or different types of aptamers. Multivalency increases the avidity of aptamers, a particularly advantageous feature that allows for significantly increased binding affinities in comparison with aptamer monomers. Another advantage of multivalency is increased aptamer stabilities that confer improved performances under physiological conditions for various applications in clinical settings. The current study aims to review the most recent developments in multivalent aptamer research. The review will first discuss structures of multivalent aptamers. This is followed by detailed discussions on design strategies of multivalent aptamer approaches. Finally, recent developments of the multivalent aptamer approach in biosensing and biomedical applications are highlighted.Entities:
Keywords: antibodies; aptamers; avidity; biosensors; detection; multivalence
Year: 2022 PMID: 35334728 PMCID: PMC8956053 DOI: 10.3390/mi13030436
Source DB: PubMed Journal: Micromachines (Basel) ISSN: 2072-666X Impact factor: 2.891
Figure 1Schematic drawing of various structures of multivalent aptamer structures.
Figure 2Schematic illustration of designs of multivalent aptamers. The optimization strategies include adding different lengths or types of spacer motifs, using a mixture of two or more different types of aptamers, and applying spatial arrangements of aptamers tailored for the geometries of target ligands and binding pockets.
Figure 3Schematic description of aptamer-cocktail-based microfluidic approach for CTC detection. (a) A microfluidic device is composed of an aptamer-conjugated silicon nanowire and a PDMS chaotic mixer. (b) When a single type aptamer is incorporated, the capturing affinity of the device is relatively weak due to the lack of synergistic binding. (c) By using an aptamer cocktail, the synergistic effects among individual aptamers lead to an enhanced capturing affinity. (d) Different aptamer cocktails are expected to have differential capture performance for CTC subpopulation recognition [89].
Figure 4Schematic drawing of constructions of 3 aptamer-DNANTs and schematic representation of thrombin-DNANT, ATP-DNANT, and insulin-DNANT [91].
Figure 5A schematic representing the inhibitory nanostructures for dengue virus with their corresponding mean EC50 (half maximal effective concentration) values. The hexagonal spacing resulted in reduced detection compared to the star-shaped spacing, despite its being the correct spacing. The schematic for the star and hexagon shows an unzipped hairpin region because potent pattern matching occurs. Other scaffolds represent the hairpins as stem–loop structures to indicate a lack of potent pattern matching ([5]).
A summary of recently published multivalent-aptamers-related papers.
| Application | Aptamer | Conjugated Material | Target | Functional | Spacer | Advantages of Multivalency | Reference |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Drug delivery | SZTI01 | RCA generated spherical DNA self-assembly | Prostate cancer membrane antigen (PCMA)-positive C4-2 cells (PCMA) | Drug-loading sites; doxorubicin | pH-sensitive oligo-T | Very stable in physiological environment; high specificity | [ |
| Drug delivery | 5TR1 | Poly(lactic-co-glycolic acid) (PGLA) dendrimer; chitosan | MCF7 cancer cells (MUC1 receptor) | Drug-loading sites; epirubicin | N/A | High affinity and specificity; good internalization | [ |
| Drug delivery | S2.2 | Lipid-capped polymer nanoparticle | Cancer cell | Drug-loading sites; vinorelbine | PEG2000 | Significantly higher uptake efficacy; enhanced cell targeting efficiency with increased density of the S2.2 aptamer | [ |
| Drug delivery | AS1411 (DNA) | Chitosan-silica nanoparticle | SKOV-3 ovarian cancer cell | Drug-loading sites; epigallocatechin gallate | N/A | Higher internalization efficacy | [ |
| Imaging/Therapeutic | AS1411 (DNA) | AuNPs; Silver nanoclusters (AgNCs) | Cancer cell | Drug-loading sites; doxorubicin; DNA-templated silver nanoclusters (signaling, fluorescent) | Adenine-rich sequence | Increased the stability of DNA probe; better internalization | [ |
| Detection and isolation | MUC1 (DNA) | Hybrid membrane; Fe3O4@SiO2 magnetic nanoparticle; Ag2S nanodots | CTC | Ag2S nanodots (signaling, near-infrared fluorescence signal) | DNA scaffold | Greatly enhanced the anti-interference from background; improve binding ability; good specificity | [ |
|
| |||||||
| Imaging | Sgc8 | Manganese dioxide nanosheet | CCRF-CEM cells | MnO2 (signaling, contrast agent); fluorescent-labeled aptamer (signaling, fluorescence) | N/A | Target-specific binding and internalization; low background signal; high sensitivity | [ |
| Chemo-photothermal therapy | AS1411 (DNA) | Black phosphorus nanosheet | PC3 cells | Doxorubicin; black phosphorus nanosheet (photothermal therapy) | N/A | Specific and high photothermal cytotoxicity for target cells | [ |
| Drug delivery system | C2NP (DNA) | DNA origami | K299 cells | Doxorubicin | N/A | Increased internalization; significantly increased aptamer bioactivity | [ |
|
| |||||||
| Detection | AS1411 | RCA generated multivalent chain | B16 cells | Signaling molecular beacon (fluorescent) | 18-bp dsDNA | Enhanced sensitivity; enhanced selectivity | [ |
| Therapeutic | LS Aptamer (DNA) | RCA generated multivalent chain | Jurkat cells (L-selectin) | Aptamer (L-selectin inhibitor) | 20 oligo-T | High avidity (103-fold higher affinity than L-selectin aptamer monomers); high specificity | [ |
| Detection/cell manipulation | Split ZY11 (DNA) | RCA generated DNA chain | Human liver cancer | Signaling probe (fluorescent) | 41 oligo-T; also served as signaling compartment by hybridization with signaling probe | Improved performance in avidity (a ~2.8-fold increase in signal-to-background-ratio); increased recognition; extended the tolerance range of temperature for target binding | [ |
| Detection | SYL3C (DNA) | RCA generated multivalent aptamer network electrode interface | CTC | Anti-EpCAM antibody; horseradish peroxidase conjugated gold nanoparticle probe (signaling. electrochemical) | 20 oligo-T | Greatly increased current response; reduced detection time | [ |
| Drug delivery | AS1411 and MUC-1 (DNA) | DNA and DNA-RNA hybrid structures | MCF-7 cells | Drug-loading site | dsDNA or siRNA duplex | Increased intracellular uptake of dual aptamer systems (increase in aptamer valency led to higher intracellular uptake) | [ |
| Detection | Zy1 | HCR generated DNA self-assembly | Human liver cancer SMMC-7721 cells | Signaling branch (fluorescent) | 10 oligo-T; HCR generated backbone | High stability in the presence of nuclease or in human serum; higher signal-to-background ratio compared with aptamer monomers; reduced dissociation constant (1/10) compared with Zy1 monomers | [ |
|
| |||||||
| Drug delivery | Sgc8 | DNA origami generated self-assembly (triangular) | Cancer cell/HeLa cell | Drug-loading sites; doxorubicin | N/A | Enhanced drug-delivery efficiency and therapeutic efficacy; decrease systemic toxicity; high stability in cell culture medium for 24 h | [ |
| Targeted gene therapy | Sgc8 | AAV2 vectors | CCRF-CEM cells (PTK7) | Gene for green fluorescent protein | DNA dendrimer | 21-fold enhanced binding affinity and enhanced resistance against nuclease degradation | [ |
| Immunotherapy | KK1B10 | HCR generated DNA self-assembly-functionalized natural killer cells | K562 cells | Natural killer cells | HCR generated backbone | Greatly increased binding avidity compared to the aptamer monomers; good stability under physiological shear stress | [ |
| Detection and capture | ZY-sls (DNA) | Cell imprinted hydrogel | SMC-7721 cells | N/A | Trifunctional cleavable crosslinker | Enhanced interaction between enhanced sites and target cells; high capture efficiency and selectivity | [ |